Patient Survey on a New CAR-T Therapy Coming to Canada

Myeloma Canada is conducting a patient survey on a new CAR-T therapy coming to Canada: idecabtagene vicleucel (ide-cel, bb2121).

Over the next few months, idecabtagene vicleucel (ide-cel, bb2121), a CAR-T cell immunotherapy ​for the treatment of multiple myeloma in adult patients will be the subject of an evaluation by the pan-Canadian Oncology Drug Review (“pCODR*) for funding consideration as a new treatment for myeloma.

To qualify, patients must have received the idecabtagene vicleucel (ide-cel, bb2121) or at least three (3) prior therapies, including:

• an immunomodulatory agent,

• a proteasome inhibitor, and

• an anti-CD38 antibody.

Myeloma Canada will share patients’ input with the review committee to ensure our community’s voice is being heard and our needs considered.

As always, patient input is particularly important, and while we cannot make promises, it could contribute to increasing availability and access to new myeloma drugs for Canadian patients affected by this disease.

Survey

This survey should only take about 12 minutes of your time. Please complete the survey by Monday, January 4, 2021, 5:00 pm EST.

Questions?

Please email Myeloma Canada at contact@myeloma.ca and indicate ‘Patient Survey’ in the subject line.